Venetoclax is safe and efficacious in relapsed/refractory AML

Chezi Ganzel*, Ron Ram, Alexander Gural, Ofir Wolach, Sharon Gino-Moor, Vladimir Vainstein, Boaz Nachmias, Arie Apel, Maya Koren-Michowitz, Oren Pasvolsky, Ronit Yerushalmi, Ivetta Danylesko, Yosef Cohen, Galit Peretz, Yakir Moshe, Miri Zektser, Shay Yeganeh, Jacob M. Rowe, Yishai Ofran

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Data from 11 Israeli centers, where venetoclax was used for relapsed/refractory AML after intensive chemotherapy, were retrospectively collected. During 2016–2019, forty patients were identified. Median age was 67 years (21–82), 60% males, median of 2(1–4) prior lines of treatment and 42% relapsed after allogeneic transplant. 62.5% of the patients received the venetoclax with hypomethylating agents and 22.5% with low dose cytarabine. Median follow-up was 5.5 months. Of the 29 patients who survived for more than two cycles of therapy, 22 (76%) achieved neutrophil recovery and 59% (n = 17) recovered also their platelet count. In 15 (52% of those who survived > 2 months), CR/CRi was confirmed by bone marrow examination. The median OS from venetoclax initiation of all the patients and of those who survived more than 2 months was 5.5 and 6.5 months, respectively. In conclusion, this study demonstrates that venetoclax is safe and active also in AML patients with advanced disease.

Original languageEnglish
Pages (from-to)2221-2225
Number of pages5
JournalLeukemia and Lymphoma
Issue number9
StatePublished - 28 Jul 2020


  • Acute myeloid leukemia
  • refractory
  • relapse
  • venetoclax


Dive into the research topics of 'Venetoclax is safe and efficacious in relapsed/refractory AML'. Together they form a unique fingerprint.

Cite this